Skip to Content

Ionis Pharmaceuticals Inc IONS

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Raising our Ionis Fair Value Estimate to $66; Narrow Moat and Long-Term Pipeline Potential

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

We're raising our Ionis fair value estimate to $66 from $58 after awarding the firm a narrow economic moat (previously none) based on the firm's spinal muscular atrophy therapy Spinraza, solid late-stage pipeline, and growing mid-stage pipeline of wholly-owned programs, all of which benefit from increasing validation of the firm's antisense oligonucleotide (RNA-based) drug technology. Third-quarter results came in as expected, with collaboration revenue poised to jump in the fourth quarter and allow the firm to meet the maintained full-year guidance for revenue over $700 million. Shares look undervalued as the firm approaches several key pipeline-related catalysts.

Read Full Analysis

Company Profile

Business Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Contact
2855 Gazelle Court
Carlsbad, CA, 92010
T +1 760 931-9200
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Aggressive Growth
Employees 817